Cerebrospinal fluid (CSF) biomarker analysis for dementia diagnostics (ie, the analysis of amyloid β₄₂, total tau and phosphorylated tau) is increasingly used in clinical practice.1 However, there is still debate among researchers and clinicians about the sensitivity and specificity of various biomarker analyses, especially when comparing dementia subtypes.2 The lack of consensus and heterogeneity for evidence on CSF biomarker use and validity is likely to have resulted in variable practices: belief in the utility of biomarker measurement has likely stimulated the use of CSF analysis in clinical practice in some places whereas elsewhere this practice probably has not been adopted at all. The extent of this variability …